

9.2 Introduction to shortages topic

Monitoring and mitigating shortages of medicines — current activities

19 November 2025 PCWP/HCPWP meeting

Monica Dias, PhD

Head of Supply and Availability of Medicines and Devices — EMA



EU-level coordination structures and activities

SPOC Working Party and MSSG

- Continuous **reporting, monitoring and discussion** of 1) critical shortages and 2) events to understand impact on medicines and **to prevent and mitigate shortages**
- Minutes of <u>SPOC WP</u> and <u>MSSG</u> meetings are publicly available. The <u>MSSG annual activity report</u> is also publicly available.

Preparedness activities

Monitoring of antibiotic supply situation for upcoming **autumn/winter season 2025/26**

- Outreach to key MAHs to obtain an overview of the expected supply situation for a set of key antibiotics.
- Liaising with **international regulators** in the southern hemisphere.
- Re-launch of social media campaign promoting prudent use of antibiotics.

Voluntary Solidarity Mechanism

- Continues to be a successful tool to identify supply of medicines in case of critical shortage, as a last resort
- The mechanism supports Members States, industry, healthcare professionals and patients by identifying available stocks and coordinating efforts in certain situations

13 VSM procedures concluded to date, all successfully* Examples include: Etoposide, Quetiapine, Olanzapine

*Support could be found via the impacted MAH, alternative MAHs or other Member States



Critical shortage management

MSSG recommendations to manage and mitigate critical shortages

Recommendation of **application of certain flexibilities** to prevent or mitigate critical shortages of medicinal products.

Examples: facilitation of the **reallocation of stock** for medicinal products, **exemptions** from national labelling requirements or **extension of shelf-life**.

Medicine Shortage Communication (MSC)

Communication to healthcare professionals on medicine shortages, adopted by MSSG in late 2024.

Replaces Direct Healthcare Professionals Communication (DHPC) when a shortage is not linked to a quality, safety or efficacy issue.

MSCs published for shortages linked to:

- withdrawal of a marketing authorisation for commercial decisions;
- disruptions in manufacturing or supply;
- unexpected increased demand.

Examples:

- MSC on Visudyne (published Sept 2025)
- MSC on Victoza (published Sept 2025)

Link to general EMA MSC webpage



MSSG recommendations on strengthening supply chains of critical medicines

Recommendations issued by MSSG to strengthen security of supply of certain medicines, based on identified supply chain vulnerabilities:

- Anti-D immunoglobulins
- Radiopharmaceuticals

Close interaction with relevant stakeholders was key to informing drafting of these recommendations:

- Experts from relevant organisations
- Experts from EMA Working Parties
- Healthcare Professionals and Patient representatives







Next presentations

Ongoing critical shortages

Update on ongoing **coordinated management** of **critical shortages**, under SPOC Working Party/MSSG.

Union list of critical medicines

Medicines for which continuity of supply is a priority, as they are critical to the proper functioning of EU healthcare systems at all times.

Shortage Prevention and Mitigation Plans (SPPs/SMPs) and Vulnerability Assessment Methodology

- **Pilot exercise** to test and optimise templates and guidance in anticipation of the proposed pharmaceutical legislation.
- SMPs will be key to inform the management of medicine shortages.
- SPPs will be key to inform the evaluate the resilience of supply chains of medicines on Union List and to identify vulnerabilities to support continued supply of those medicines.





Thank you

Follow us







